Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study established a murine chronic graft-versus-host disease model with scleroderma features, showing typical skin changes and cellular infiltrates associated with the condition.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.

This paper discusses the evolving understanding of psoriasis pathogenesis with no new clinical findings; the authors highlight the role of T-cell plasticity and regulatory cells, calling for further clinical applications using single-cell technologies.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This study suggests that the T allele of the SNP rs2476601 in the PTPN22 gene may increase the risk of alopecia areata, although further studies are necessary to validate this finding across different populations.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

In this study, researchers found that patients with alopecia areata had a significant increase in NKG2D+CD4+ T cell levels in their blood compared to healthy controls.

This study found significant upregulation of IDO-1 and IDO-2 in human basal cell carcinomas, suggesting that IDO production may confer immune privilege characteristics to the tumors, potentially impacting their growth.

This study found that patients with alopecia areata have lower levels of sCD83, a protein which, when supplemented in a mouse model, reversed disease symptoms and supported regulatory T cell proliferation, possibly by interacting with IDO activity.

The authors developed a severe mouse model of chronic graft-versus-host disease and reported that rapamycin treatment improved survival compared to placebo, potentially by promoting regulatory T cell expansion.

This study suggests that a newly identified KRT 71 gene variant may be responsible for curly hair in Curly Coated Retrievers and potentially contributes to follicular dysplasia.

This study found that RNase L acts as a regeneration repressor gene in mammals, as seen in Rnasel-/- mice which showed increased regenerative capacity and elevated Wound Induced Hair Neogenesis through enhanced IL-36α signaling, suggesting a tradeoff between regeneration and immune regulation.

This study found that PDGF-D acts as a potent mitogenic factor in adipose-derived stem cells, enhancing their proliferation, migration, and growth factor expression, suggesting its use as a preconditioning agent for ASC transplantation.

This study found that programmed death-ligand 1 (PD-L1) levels correlated with the severity of alopecia areata, suggesting its potential as an indicator and possible target for new treatments.

In this study, ALR was found to enhance both the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells, potentially through specific signaling pathways.

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

This study found that patients with alopecia areata have distinct mRNA and lncRNA expression profiles between normal and bald scalp areas, identifying differentially expressed genes and revealing potential biomarkers for diagnosis, with keratin family genes possibly playing a key role in the disease's pathogenesis.

This study found that silencing the circular RNA circNlgn in mice reduced doxorubicin-induced cardiofibrosis and cardiomyocyte apoptosis, suggesting potential therapeutic strategies for minimizing heart-related side effects in cancer treatment.

This study identified a high proportion of dual TCR Treg cells in both lymphoid and non-lymphoid tissues of mice, revealing their tissue specificity, TCR repertoire characteristics, and functional phenotypes.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

This study identified hsa_circ_0001079 as a potential diagnostic marker for androgenetic alopecia, suggesting it may play a role in the condition by interacting with specific microRNAs.

This study found that CD200-negative human hair follicle bulge cells have a higher hair-regenerative capability compared to CD200-positive cells, suggesting that reduced CD200 expression may enhance hair regeneration, providing insights for improving bulge cell-based hair restoration techniques.

This study found that RXR and RAR proteins were detectable in normal human skin, suggesting they may play a role in epidermal cell differentiation and hair and gland physiology.

In this study, researchers identified 173 differentially expressed genes in alopecia areata patients linked to immune and hair follicle pathways, constructed a regulatory network involving mRNA, miRNA, and lncRNA, and highlighted CD8A and FOXD2-AS1 as potential diagnostic markers and therapeutic targets.

This study demonstrated immunological cross-reactivity between mycobacterial heat-shock protein 65 and human epidermal cytokeratin 1/2, suggesting that this cross-reactive epitope might play a role in skin diseases.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.